Press Releases

Press Releases

Indaptus Therapeutics to Present at JMP Securities Life Sciences Conference

June 9, 2022

NEW YORK (June 9, 2022) – Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), today announced that Jeffrey A. Meckler, Chief Executive Officer of Indaptus, will present a corporate overview at the JMP Securities Life Sciences Conference on Thursday, June 16, 2022 at 2:30 p.m. ET in New York City. read more →

Indaptus Therapeutics to Present at Jefferies Healthcare Conference

June 3, 2022

NEW YORK (June 3, 2022) – Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), today announced that Jeffrey A. Meckler, Chief Executive Officer of Indaptus, will present a corporate overview at the Jefferies Healthcare Conference on Friday, June 10, 2022 at 12:45 p.m. ET. A live webcast of the presentation read more →

Indaptus Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Decoy20 in Solid Tumors

May 19, 2022

NEW YORK (May 19, 2022) – Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for a Phase 1 clinical trial in patients with advanced solid tumors where currently approved therapies have read more →

Indaptus Therapeutics to Present at H.C. Wainwright Global Investment Conference

May 18, 2022

NEW YORK (May 18, 2022) – Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), today announced that Jeffrey A. Meckler, Chief Executive Officer of Indaptus, will present a corporate overview at the H.C. Wainwright Global Investment Conference on Wednesday, May 25, 2022 at 8:30am ET. A live webcast of the read more →

Indaptus Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

May 12, 2022

Announces Submission of Investigational New Drug (IND) Application for Decoy20 On Track to Initiate Phase 1 Clinical Trial of Decoy20 for Treatment of Solid Tumors in Second Half of 2022   NEW YORK (May 12, 2022) – Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), today announces financial results for read more →

Indaptus Therapeutics to Present at 2nd Annual Chronic HBV Drug Development

April 20, 2022

NEW YORK (April 20, 2022) – Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), today announced that Michael J. Newman, Ph.D., Founder and Chief Scientific Officer, will present at the 2nd Annual Chronic HBV Drug Development Summit taking place from April 25-27, 2022 in Boston, MA. Presentation Details: Title: Driving read more →

Indaptus Therapeutics to Present at Maxim Group 2022 Virtual Growth Conference

March 23, 2022

NEW YORK (March 23, 2022) – Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), today announced that Jeffrey Meckler, Chief Executive Officer, will participate in a pre-recorded presentation at the Maxim Group 2022 Virtual Growth Conference made available Monday, March 28, 2022 at 9:00 a.m. ET.   An audio webcast read more →

Indaptus Therapeutics Reports Fourth Quarter and Year End 2021 Financial Results and Provides Corporate Update

March 21, 2022

NEW YORK (March 21, 2022) – Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), today announces financial results for the fourth quarter and year ended December 31, 2021 and provides a corporate update. “We enter 2022 excited about the future for Indaptus as we continue to advance our clinical read more →

Indaptus Therapeutics to Present at 3rd Annual STING & TLR-Targeting Therapies Summit

March 17, 2022

NEW YORK (March 17, 2022) – Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), today announced that Michael J. Newman, Ph.D., Founder and Chief Scientific Officer, will present and participate in a panel discussion at the 3rd Annual STING & TLRTargeting Therapies Summit taking place virtually from March 22-24, read more →

Indaptus Therapeutics to Present at 34th Annual ROTH Conference

March 7, 2022

NEW YORK (March 7, 2022) – Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), today announced that Jeffrey Meckler, Chief Executive Officer, will participate in an on demand pre-recorded presentation at the 34th Annual ROTH Conference which is taking place March 14 – 15, 2022. An audio webcast of read more →